PubRank

Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood

Clinical Trial ID NCT02533895

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02533895

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Decoding the patterns of self and nonself by the innate immune system. Science 2002 7.19
3 Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000 6.45
4 Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997 5.48
5 Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000 5.13
6 Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002 4.02
7 Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005 3.29
8 Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990 3.15
9 Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006 2.85
10 Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987 2.81
11 Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003 2.64
12 Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A 1996 2.52
13 T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995 2.07
14 Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2008 1.95
15 Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996 1.72
16 Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993 1.54
17 Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997 1.49
18 Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008 1.49
19 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 1.44
20 A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992 1.44
21 The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990 1.31
22 Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A 1999 1.30
23 Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996 1.22
24 Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994 1.17
25 Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci U S A 1994 1.12
26 Vaccination against human cancers (review). Int J Oncol 2000 1.10
27 Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med 2008 0.98
28 Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res 1999 0.94
29 Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 2005 0.93
30 Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 2007 0.92
31 Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother 2005 0.89
32 Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 2010 0.85
33 Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997 0.82
34 Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a. Melanoma Res 1994 0.77
35 Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 1991 0.77
Next 100